In both studies, mepolizumab, when added to triple therapy, showed significant reductions in flare-up rates compared to a placebo and prolonged the time to the first severe flare-up. Now, NICE and the Scottish Medicines Consortium will evaluate the treatment for potential coverage by the NHS.